Article Text

Download PDFPDF
Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis
  1. Laura Pirilä1,
  2. Tuulikki Sokka2,
  3. Markku J Kauppi3,
  4. Vappu M Rantalaiho4,
  5. Eero Mervaala5,
  6. Kari Puolakka6
  1. 1Department of Rheumatology, TYKS, Turku, Finland
  2. 2Jyvaskyla Central Hospital, Jyvaskyla, Finland
  3. 3Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
  4. 4Tampere University Hospital, Tampere, Finland
  5. 5Farmakologian osasto, Helsingin Yliopisto Laaketieteellinen tiedekunta, Helsinki, Finland
  6. 6Department of Medicine, Lappeenranta Central Hospital, Lappeenranta, Finland
  1. Correspondence to Professor Tuulikki Sokka, Jyvaskyla Central Hospital, Keskussairaalantie 19, Jyvaskyla 40620, Finland; tuulikki.sokka{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

This letter is inspired by the ‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update’.1

There is no question that we are in full agreement with the overarching principles of the EULAR recommendations. What goes against our principles, however, is the tone of the bullet points. …

View Full Text


  • Contributors All co-authors have contributed to this letter and agree with its contents.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles